Global coagulation assays in patients with multiple myeloma and monoclonal gammopathy of unknown significance

Both multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) are associated with increased venous thromboembolism (VTE) and arterial thrombosis [1]. The thrombogenicity of myeloma is multi-fold with current VTE risk stratification focusing predominantly on clinical factors. Key to augmenting our clinical risk assessment model to identify patients who may benefit from thromboprophylaxis is a predictive biomarker. Current coagulation testing are inadequate as they measure only the time to clot formation, making them poor indicators of a hypercoagulable state.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research